Keenova Therapeutics

Keenova Reports Third Quarter 2026 Financial Results

Continued Strong Performance Driven by Growth in Acthar® Gel1 and XIAFLEX®2 XIAFLEX Pipeline Advances: Plantar Fibromatosis sBLA Submission Expected…